Claire M. Rooney
Glasgow, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Evaluation of radiotherapy dose and survival outcomes for teenagers, and young adults with nasopharyngeal carcinoma in UK & Ireland.
Journal: Oral oncology
Published: December 05, 2025
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Journal: British journal of cancer
Published: September 25, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: September 19, 2023
Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue.
Journal: Clinical proteomics
Published: September 01, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: August 18, 2023
Radiological abnormalities persist following COVID-19 and correlate with impaired health-related quality of life: a prospective cohort study of hospitalised patients.
Journal: BMJ open respiratory research
Published: July 28, 2023
Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma.
Journal: Frontiers in toxicology
Published: April 05, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Journal: NPJ breast cancer
Published: October 19, 2022
Delivering Cognitive Stimulation Therapy (CST) Virtually: Developing and Field-Testing a New Framework.
Journal: Clinical interventions in aging
Published: November 18, 2021
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 16, 2020
The pathogenesis of mesothelioma is driven by a dysregulated translatome.
Journal: Nature communications
Published: October 23, 2020
Last Updated: 09/26/2026